M A Petri

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus
    Adnan N Kiani
    Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Rheumatology (Oxford) 52:2071-6. 2013
  2. doi request reprint Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
    Michelle A Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Arthritis Rheum 65:2143-53. 2013
  3. pmc Effect of pregnancy on serum cytokines in SLE patients
    Andrea Doria
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, Padova, 35128, Italy
    Arthritis Res Ther 14:R66. 2012
  4. pmc Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Arthritis Rheum 65:1865-71. 2013
  5. pmc Predictors of self-reported health-related quality of life in systemic lupus erythematosus
    Adnan N Kiani
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Rheumatology (Oxford) 52:1651-7. 2013
  6. pmc Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 65:1011-21. 2013
  7. pmc Unmet medical needs in systemic lupus erythematosus
    Aisha Lateef
    Division of Rheumatology, University Medicine Cluster, National University Health System, 1E Kent Ridge Road, Singapore 119074, Singapore
    Arthritis Res Ther 14:S4. 2012
  8. pmc Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Arthritis Rheum 64:4021-8. 2012
  9. pmc Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    Arthritis Rheum 64:2677-86. 2012
  10. pmc Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
    Lindsey E Romick-Rosendale
    Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA
    Arthritis Res Ther 13:R199. 2011

Research Grants

  1. Brain Connections
    Michelle Petri; Fiscal Year: 2006
  2. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
  3. Lupus Cohort
    Michelle Petri; Fiscal Year: 2006
  4. HOPKINS LUPUS COHORT
    Michelle Petri; Fiscal Year: 2001
  5. HOPKINS LUPUS COHORT
    Michelle A Petri; Fiscal Year: 2010

Detail Information

Publications50

  1. pmc Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus
    Adnan N Kiani
    Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Rheumatology (Oxford) 52:2071-6. 2013
    ..We determined whether levels of vitamin D at baseline were associated with subclinical measures of atherosclerosis, or with changes in subclinical measures over 2 years...
  2. doi request reprint Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
    Michelle A Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Arthritis Rheum 65:2143-53. 2013
    ..To identify predictors of moderate-to-severe systemic lupus erythematosus (SLE) flare in 562 patients treated with standard therapy alone in phase III belimumab trials, and to evaluate the impact of standard therapies on preventing flares...
  3. pmc Effect of pregnancy on serum cytokines in SLE patients
    Andrea Doria
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, Padova, 35128, Italy
    Arthritis Res Ther 14:R66. 2012
    ..The aim of this study was to evaluate an extensive panel of cytokines involved in immune regulation during pregnancy in patients with systemic lupus erythematosus (SLE) and in healthy women...
  4. pmc Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Arthritis Rheum 65:1865-71. 2013
    ..To investigate whether an increase in vitamin D levels in patients with systemic lupus erythematosus (SLE) was associated with improvement in disease activity...
  5. pmc Predictors of self-reported health-related quality of life in systemic lupus erythematosus
    Adnan N Kiani
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Rheumatology (Oxford) 52:1651-7. 2013
    ..The objective of our study was to identify predictors of HRQOL using SF-36 among patients with SLE enrolled in a 2-year randomized controlled trial (RCT)...
  6. pmc Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 65:1011-21. 2013
    ..To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE)...
  7. pmc Unmet medical needs in systemic lupus erythematosus
    Aisha Lateef
    Division of Rheumatology, University Medicine Cluster, National University Health System, 1E Kent Ridge Road, Singapore 119074, Singapore
    Arthritis Res Ther 14:S4. 2012
    ..The current review will highlight some of the outstanding unmet challenges in the management of this complex disease...
  8. pmc Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Arthritis Rheum 64:4021-8. 2012
    ..We analyzed data from a large SLE cohort to identify variables associated with rates of damage accrual as measured by the SDI...
  9. pmc Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    Arthritis Rheum 64:2677-86. 2012
    ....
  10. pmc Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
    Lindsey E Romick-Rosendale
    Department of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA
    Arthritis Res Ther 13:R199. 2011
    ....
  11. pmc Seasonal variation in the activity of systemic lupus erythematosus
    Alí Duarte-García
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Rheumatol 39:1392-8. 2012
    ..To determine whether there is any seasonal variation in the activity of systemic lupus erythematosus (SLE) overall and by individual organs...
  12. pmc Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis
    Adnan N Kiani
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Rheumatol 39:1231-7. 2012
    ..Both VCAM-1 and NGAL have been found at high levels in the urine of patients with active lupus nephritis. We investigated both as potential biomarkers for lupus nephritis...
  13. pmc Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus
    Janet W Maynard
    Johns Hopkins University School of Medicine, 1830 East Monument St, Suite 7500, Baltimore, MD 21205, USA
    J Rheumatol 39:777-83. 2012
    ..We investigated whether education or income levels are associated with cardiovascular risk factors and outcomes in SLE...
  14. pmc Differences between male and female systemic lupus erythematosus in a multiethnic population
    Tze Chin Tan
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    J Rheumatol 39:759-69. 2012
    ..Comparisons were made between male and female patients with SLE in the Hopkins Lupus Cohort...
  15. doi request reprint Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study
    Michelle Petri
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Suite 7500, Baltimore, Maryland 21205, USA
    J Rheumatol 36:2476-80. 2009
    ..We determined the prevalence of and risk factors for British Isles Lupus Activity Group (BILAG) flare in patients with systemic lupus erythematosus (SLE)...
  16. pmc High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial
    Michelle Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 62:1487-93. 2010
    ..We undertook this study to compare the efficacy and safety of the standard regimen versus a high-dose IV cyclophosphamide regimen...
  17. doi request reprint Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort
    M Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland 21205, USA
    Lupus 19:419-23. 2010
    ..Anti-phospholipid antibodies are not associated with atherosclerosis...
  18. doi request reprint Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University, Suite 7500, Baltimore, Maryland 21205, USA
    J Rheumatol 37:2032-8. 2010
    ..The natural history of cognitive dysfunction in newly diagnosed SLE is unknown. We examined the association of depression and cognitive performance in newly diagnosed SLE...
  19. doi request reprint Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus
    Taraneh Mehrani
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    J Rheumatol 38:64-8. 2011
    ..Multiple studies have found a high prevalence of IgA anti-ß(2)-GPI in systemic lupus erythematosus (SLE). We determined the frequency and associations of IgA anti-ß(2)-GPI in a cohort of patients with SLE...
  20. doi request reprint Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    Curr Rheumatol Rep 13:77-80. 2011
    ..This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies...
  21. doi request reprint Lupus Atherosclerosis Prevention Study (LAPS)
    M A Petri
    Professor of Medicine, Johns Hopkins University, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Ann Rheum Dis 70:760-5. 2011
    ..A study was undertaken to investigate whether treatment with statins would reduce subclinical measures of atherosclerosis over a 2-year period...
  22. doi request reprint Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Int J Rheum Dis 14:1-5. 2011
    ..Greater appreciation of cognitive impairment and of lupus myelitis is now possible. Pregnancy risks are better characterized. However, the greatest unmet challenge remains atherosclerosis...
  23. pmc Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial
    Michelle Petri
    Johns Hopkins University, Baltimore, MD 21205, USA
    Semin Arthritis Rheum 41:194-202. 2011
    ..We investigated whether it had benefit for SLE cognitive impairment...
  24. doi request reprint Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus
    M Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Lupus 18:980-9. 2009
    ..In summary, although higher IFNr scores were associated with greater disease activity, IFNr scores of individual patients did not correlate with changes in disease severity or flare risk...
  25. ncbi request reprint Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Rheumatol 35:2348-54. 2008
    ..We wished to determine the prevalence of cerebral atrophy and focal lesions in a cohort of patients with newly diagnosed systemic lupus erythematosus (SLE) and the association of these brain abnormalities with clinical characteristics...
  26. ncbi request reprint Cyclophosphamide: new approaches for systemic lupus erythematosus
    M Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Lupus 13:366-71. 2004
    ..This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide...
  27. ncbi request reprint Prospective study of systemic lupus erythematosus pregnancies
    M Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Lupus 13:688-9. 2004
    ..Pregnancy loss occurred in 14%. Active SLE contributes to both preterm birth and to pregnancy loss. In addition, even in a first pregnancy, the presence of the lupus anticoagulant is associated with an increased risk of pregnancy loss...
  28. ncbi request reprint Classification criteria for systemic lupus erythematosus: a review
    M Petri
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lupus 13:829-37. 2004
    ..These critical reviews, discussed at the Lund, Sweden, meeting in 2003, will be useful to the clinician and to the researcher. This paper reviews and critiques previous classification attempts...
  29. ncbi request reprint Review of classification criteria for systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 31:245-54, vi. 2005
    ..Other classification criteria, emphasizing weighting or recursive partitioning, exist, but they are more cumbersome. Revised criteria are needed, not just for systemic lupus erythematosus, but also for chronic cutaneous lupus...
  30. ncbi request reprint Systemic lupus erythematosus: 2006 update
    Michelle Petri
    Department of Medicine, Lupus Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Rheumatol 12:37-40. 2006
  31. ncbi request reprint Management of antiphospholipid syndrome in pregnancy
    Michelle Petri
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument 7500, East Baltimore Campus, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 32:591-607. 2006
    ..New research on the role of complement activation in murine APS pregnancy loss may change therapeutic options in the future...
  32. ncbi request reprint Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus
    Adnan Kiani
    Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland 20852, USA
    J Rheumatol 34:969-72. 2007
    ..We determined the association of sCD154 with coronary calcium and carotid plaque at the baseline visit of the Lupus Atherosclerosis Prevention Study...
  33. pmc The Hopkins Lupus Pregnancy Center: ten key issues in management
    Michelle Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 33:227-35, v. 2007
    ..These key issues will be examined in this chapter...
  34. ncbi request reprint Monitoring systemic lupus erythematosus in standard clinical care
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 E Monument St Suite 7500, Baltimore, MD 21205, USA
    Best Pract Res Clin Rheumatol 21:687-97. 2007
    ..Disease activity indices and a cumulative history summary can be used to track complicated patients over time. Monitoring guidelines for damage from the disease and for the toxicity of treatment are available...
  35. doi request reprint Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD 21205, USA
    Arthritis Rheum 58:2453-9. 2008
    ..To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE)...
  36. ncbi request reprint Cognitive function in a systemic lupus erythematosus inception cohort
    Michelle Petri
    Johns Hopkins University, Baltimore, MD, USA
    J Rheumatol 35:1776-81. 2008
    ..Measurable cognitive impairment occurs in 30-75% of patients with systemic lupus erythematosus (SLE). We compared cognitive functioning in recently-diagnosed SLE patients and normal controls...
  37. doi request reprint Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index
    Michelle Petri
    Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Arthritis Rheum 58:1784-8. 2008
    ..To develop a measure of renal activity in systemic lupus erythematosus and use it to develop a renal response index...
  38. doi request reprint Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response
    Michelle Petri
    Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Arthritis Rheum 58:1789-95. 2008
    ..To assess the degree to which physicians agree with each other and with ratings obtained with 3 existing responder indices, in rating the response to treatment of lupus nephritis...
  39. doi request reprint Sex hormones and systemic lupus erythematosus
    M Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21093, USA
    Lupus 17:412-5. 2008
    ..The role of estrogen, prolactin, pregnancy and androgen (including DHEA) in SLE is reviewed. A comlex interaction of multiple sex hormones is involved in SLE...
  40. pmc Disease activity assessment in SLE: do we have the right instruments?
    Michelle Petri
    Johns Hopkins University School of Medicine, Division of Rheumatology, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Ann Rheum Dis 66:iii61-4. 2007
    ..This has led, understandably, to concern that there is something wrong with SLE trial designs, particularly with SLE disease activity indices...
  41. pmc Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus
    Adnan N Kiani
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine Baltimore, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA
    Rheumatology (Oxford) 50:2071-9. 2011
    ..Cardiovascular disease remains the major cause of death in SLE. We assessed the degree to which cardiovascular risk factors (CVRFs) and disease activity were associated with 2-year changes in measures of subclinical atherosclerosis...
  42. doi request reprint IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus
    Taraneh Mehrani
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Rheumatol 38:450-3. 2011
    ..We investigated whether IgM anti-ß(2)-glycoprotein I (anti-ß(2)-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE)...
  43. ncbi request reprint Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group
    Sean J Wollaston
    Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Rheumatol 31:2390-4. 2004
    ..We attempted to determine whether these validated instruments were useful components in characterizing response in the setting of a clinical trial...
  44. ncbi request reprint Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares
    Irene M Vasiliu
    Department of Medicine, State University of New York at Buffalo, New York, USA
    J Rheumatol 33:1878-80. 2006
    ..Our experience suggests that G-CSF therapy should be used with considerable caution in patients with SLE...
  45. ncbi request reprint Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep
    Robin L Brey
    Neurology 61:9-10. 2003
  46. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  47. ncbi request reprint Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease
    Michelle A Petri
    J Rheumatol 31:2329-30. 2004
  48. pmc The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus
    Kathleen E Sullivan
    Allergy Immunology, The Children s Hospital of Philadelphia, 34th Street and Civic Ctr Boulevard, Philadelphia, PA 19104, USA
    Clin Immunol 123:74-81. 2007
    ..Histone acetylation, associated with increased transcriptional competence of TNFalpha, may play a role in certain inflammatory aspects of the disease...
  49. ncbi request reprint The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial
    Jill P Buyon
    Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA
    Ann Intern Med 142:953-62. 2005
    ..There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE)...
  50. ncbi request reprint Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
    Michelle A Petri
    Department of Medicine, John Hopkins Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 46:1820-9. 2002
    ..5 mg/day for 2 months or longer while maintaining stable or reduced disease activity in steroid-dependent women with systemic lupus erythematosus (SLE)...

Research Grants19

  1. Brain Connections
    Michelle Petri; Fiscal Year: 2006
    ..abstract_text> ..
  2. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  3. Lupus Cohort
    Michelle Petri; Fiscal Year: 2006
    ..Fourth, we will assess, in 100 SLE patients with and 100 without fibromyalgia, the frequency of autonomic neuropathy and the correlation with health status. ..
  4. HOPKINS LUPUS COHORT
    Michelle Petri; Fiscal Year: 2001
    ..Understanding the basis of change in health status measures is necessary to justify the future use of these measures as efficacy outcomes in clinical trials. ..
  5. HOPKINS LUPUS COHORT
    Michelle A Petri; Fiscal Year: 2010
    ..This project addresses three challenges: hardening of the arteries, blood clots, and lupus kidney disease in collaboration with other rheumatologists and radiologists. ..